Bharat Biotech's Covaxin has demonstrated 77.8% efficacy in phase 3 trials, reported ANI quoting sources. The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee of the Indian drug regulator. The panel has approved the trial data which is based on 25,800 subjects. Covaxin is one of the three Covid vaccines currently in use in India.